
BYOmass Inc Profile last edited on: 8/18/20
CAGE: 7ZM19
UEI: N57BMT7GFJG6
Business Identifier: Therapeutics to modulate central control of metabolism associated with aging and age-related chronic illnesses. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
161 Pantry Road
Sudbury, MA 01776
Sudbury, MA 01776
(860) 501-1575 |
N/A |
N/A |
Location: Single
Congr. District: 03
County: Middlesex
Congr. District: 03
County: Middlesex
Public Profile
BYOMass Inc. is a preclinical metabolic disease biotech structured around development of therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses. In metabolic disease space, the focus / target is primarily on tissues - liver, muscle and pancreas. BYOmass principals indicate their focus will instead be focusing on how the brain controls metabolism - "more specifically ,how the hypothalamus and the brain stem performâ¦to help maintain food intake, body weight and blood pressure.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 1 | NIH | $354,845 | |
Project Title: Identification of First in Class Small Molecule GFRAL Blockers for the Prevention and Reversal of Cancer Anorexia-Cachexia | ||||
2019 | 1 | NIH | $299,871 | |
Project Title: Identification of Bi-Specific Antibodies to Inhibit Gdf-15 and Activin a for Anorexia-Cachexia | ||||
2019 | 1 | NIH | $299,871 | |
Project Title: Identification of Bi-Specific Antibodies to Inhibit GDF-15 and Activin a for Anorexia-Cachexia |
Key People / Management
Vivienne Margaret Jackson -- Founder and CEO